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During further characterization of the Hi-Myc and Lo-Myc prostate cancer transgenic mice, we discovered that 34 amino acids of additional
sequence (derived from the Bluescript multiple cloning site) were inadvertently added to the C terminus of the human c-Myc protein during
subcloning, creating an unintended C-terminal tag. Consequently, the transgenic Myc protein (Myc-Tg) runs with higher mobility than en-
dogenous Myc (85–90 kDa versus 65 kDa). It is unlikely that the additional C-terminal sequences alter Myc function because the transform-
ing activity of Myc-Tg was comparable to that of Myc in NIH3T3 fibroblast transformation assays (Table 1). Furthermore, proliferation of Myc-
CaP cells, a new line derived from Hi-Myc prostate tumors, is restored by ectopic Myc expression when Myc-Tg levels are lowered by
androgen withdrawal (Watson et al., 2005). Since untagged human Myc can compensate for loss of Myc-Tg function, we consider the
Myc-Tg protein that is expressed in Hi-Myc and Lo-Myc to be an epitope-tagged Myc protein. Since the publication of our findings in mice,
others have reported that overexpression of wild-type c-Myc is sufficient to induce tumor formation of normal human prostatic epithelial cells
in a tissue recombination assay (Williams et al., 2005), confirming the oncogenic potential of Myc in prostate cancer.
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Table 1. Soft agar transformation assay
Cell type Number of foci
3T3 1
3T3 Myc-wt 8
3T3 Myc-Tg 9
3T3 c-term 34 AA 2
3T3 Ras(KV12) 136
3T3 Myc-wt + Ras(KV12) 202
3T3 Myc-Tg + Ras(KV12) 224
3T3 c-term 34 aa + Ras(KV12) 168
NIH3T3 cells were transfected with a plasmid expressing Myc-wt, Myc-Tg, or the 34 amino acid tail added to the Myc-Tg alone or together with a plasmid
expressing activated Ras(KV12) as indicated then grown in soft agar. The number of foci obtained after growth in soft agar is averaged in the column
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